Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6075106 | 1.00 | RAB9A (0.59) | RAB9ATSHRHSD17B10LMNACYP1A2 | |
| SCHEMBL10926521 | 0.92 | KMT2A (0.53) | RAB9ATSHRHSD17B10LMNACYP1A2 | |
| SCHEMBL10492673 | 0.90 | RAB9A (0.66) | RAB9ATSHRHSD17B10LMNACYP1A2 | |
| SCHEMBL773087 | 0.89 | MAOB (0.59) | RAB9ATSHRHSD17B10HIF1AMAOB | |
| SCHEMBL5878404 | 0.86 | L3MBTL1 (0.61) | TSHRHSD17B10LMNAHIF1AKMT2A | |
| SCHEMBL4019175 | 0.86 | L3MBTL1 (0.61) | TSHRHSD17B10LMNAHIF1AKMT2A | |
| SCHEMBL2021875 | 0.86 | L3MBTL1 (0.61) | TSHRHSD17B10LMNAHIF1AKMT2A | |
| SCHEMBL25152953 | 0.85 | MAOB (0.60) | RAB9ALMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL29162424 | 0.85 | MAOB (0.60) | RAB9ALMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL21634013 | 0.85 | KMT2A (0.48) | RAB9ATSHRHSD17B10MAOBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6743787-B2 | FOR THERAPY OF METABOLIC DISORDERS MEDIATED BY INSULIN RESISTANCE OR HYPERGLYCEMIA IN A MAMMAL | WYETH | 2004-06-01 | — | — | US | disclosed |
| US-6649603-B2 | For therapy of metabolic disorders related to insulin resistance or hyperglycemia | WYETH | 2003-11-18 | — | — | US | disclosed |
| EP-1328512-A2 | CYCLYLAMINE SULFONAMIDES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | Wyeth (US) | 2003-07-23 | — | — | EP | disclosed |
| US-20030027797-A1 | Cyclylamine sulfonamides as beta-3 adrenergic receptor agonists | WYETH (US) | 2003-02-06 | — | — | US | disclosed |
| US-20030027795-A1 | N-(4-sulfonylaryl)cyclylamine-2-hydroxyethylamines as beta-3 adrenergic receptor agonists | WYETH | 2003-02-06 | — | — | US | disclosed |
| US-6498170-B2 | 4-((2S)-3-(1-(4-BUTOXY-BENZENESULFONYL)-AZETIDIN-3-YLAMINO)-2 -HYDROXY- PROPOXY)-PHENOL FOR EXAMPLE; HYPOGLYCEMIC AGENT; INCREASING LEAN MEAT TO FAT RATIO IN MAMMALS | WYETH | 2002-12-24 | — | — | US | disclosed |
| US-6444685-B1 | THERAPY FOR METABOLISM DISEASES; DIETETICS; ANTIDIABETIC AGENTS | WYETH | 2002-09-03 | — | — | US | disclosed |
| US-20020028797-A1 | N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION | 2002-03-07 | — | — | US | disclosed |
| US-20020022605-A1 | Cyclamine sulfonamides as beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-02-21 | — | — | US | disclosed |
| WO-2002006221-A2 | CYCLYLAMINE SULFONAMIDES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
| WO-2002006274-A1 | N-(4-SULFONYLARYL)CYCLYLAMINE-2-HYDROXYETHYLAMINES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
| EP-0171702-A1 | Benzoxazinone derivatives, preparation and use | BEECHAM GROUP PLC (GB) | 1986-02-19 | — | — | EP | disclosed |
| EP-0171760-A2 | Substituted phenoxypropylaminoethoxyphenoxyacetamides | BEECHAM GROUP PLC (GB) | 1986-02-19 | — | — | EP | disclosed |
| EP-0064487-A1 | New substituted 3-(parasubstituted)phenoxy-1-alkylamino-propanol-2-s, as well as process for their preparation, pharmaceutical preparations containing same, and method for treating cardiac failure | Aktiebolaget Hässle (SE) | 1982-11-10 | — | — | EP | disclosed |
| US-4336267-A | Heart active compounds and methods of use | AKTIEBOLAGET HASSLE (SE) | 1982-06-22 | — | — | US | disclosed |
| US-4244969-A | (P-HYDROXYPHENOXY)PROPANOLAMINE DERIVATIVES USEFUL AS B-RECEPTOR STIMULANTS | AKTIEBOLAGET HASSLE (SE) | 1981-01-13 | — | — | US | disclosed |
| US-4020071-A | B-ADRENOLYTIC, ANTIARRHYTHMIA | CASSELLA FARBWERKE MAINKUR AKTIENGESELLSCHAFT (DT) | 1977-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022605-A1 | Cyclamine sulfonamides as beta-3 adrenergic receptor agonists | ADRB3, ADRB1, ADRB2 | RAB9A 3212/4885TSHR 59/4885HSD17B10 1280/4885 |
| US-20030027797-A1 | Cyclylamine sulfonamides as beta-3 adrenergic receptor agonists | ADRB3, ADRB1, ADRB2 | RAB9A 2942/4885TSHR 57/4885HSD17B10 1400/4885 |
| US-20030027795-A1 | N-(4-sulfonylaryl)cyclylamine-2-hydroxyethylamines as beta-3 adrenergic receptor agonists | ADRB3, ADRB1, ADRB2 | RAB9A 1847/4885TSHR 94/4885HSD17B10 517/4885 |
| US-20020028797-A1 | N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists | ADRB3, ADRB1, ADRB2 | RAB9A 1938/4885TSHR 96/4885HSD17B10 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.